Zoetis Inc (ZTS) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Total Assets Chart for Zoetis Inc

Zoetis Inc (ZTS) total assets for FY2025 were USD 15.5B, a 8.6% change from FY2024. Zoetis Inc's total assets grew from USD 5.3B in 2010 to USD 15.5B in 2025 (192.7% over 15 years). Total assets compound annual growth rate: 5-year CAGR of 2.6%, 10-year CAGR of 6.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$30.49B
Implied Share Price
$73.79
Enterprise Value
$38.06B
Revenue (TTM)
$9.53B
EBITDA
$4.07B
Profit Margin
27.69%
Trailing P/E
12.04
Forward P/E
11.90
Price/Book (MRQ)
9.69
Price/Sales (TTM)
3.20
EV/EBITDA
9.47
EV/Revenue
4.00
Dividend Yield
2.72%
Book Value
$7.84
Free Cash Flow (FY2025)
$2.28B
Free Cash Flow Yield
7.49%

Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.